Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month
However, FAERS has well-known limitations: Reports are spontaneous and incomplete Reporting stimulated by media attention and warnings No denominator (unknown number of exposed users) Thyroid cancer not subtype-adjudicated Confirmation bias (clinicians primed to connect drug and outcome) FAERS can answer: "Is this being reported more?" It cannot answer: "Does this drug cause thyroid cancer?" Appropriate Use of FAERS: FAERS findings are hypothesis-generating signals requiring controlled observational worknot evidence of causality
Ensuring clear safety disclosures, especially around compounded drugs Compounded drugs are custom medications prepared by a pharmacist for an individual patient, often when an FDA-approved product is not medically appropriate, or when the approved drug is in short supply and meets the conditions set out in federal law
It is that approved products give clinicians and patients a clearer framework for discussing risks, expected monitoring, prescription requirements, and affordability
This new delivery method gives patients more flexibility in how they take Wegovy, while still receiving provider-guided care through Shed
Diabetes prescriptions may be more stable and predictable, while obesity-related prescriptions can involve more frequent dose adjustments, therapy initiation, and discontinuation
